Vyome shares rise 10.42% premarket after successfully funding Phase 3 study with minimal dilution via ATM facility.

Vyome Holdings surged 10.42% in premarket trading following its announcement that it successfully funded its VT-1953 Phase 3 study via its At-The-Market facility, securing $5.29 million at a 59.2% premium to the prior close. The company emphasized minimal dilution (15% total) and sufficient liquidity to deliver interim Phase 3 results for its MFW drug by mid-2027. Management highlighted rejecting higher-dilution funding offers and underscored a third-party valuation estimating VT-1953 at $1 billion post-trial completion. The $9.5 million cash balance and focus on cost-efficient execution reinforced confidence in the company’s capital strategy, aligning with the stock’s upward move.